Skip to main content
Professional Technical IVT

fingolimod

Pronunciation: fin-GOL-i-mod

An oral sphingosine-1-phosphate receptor modulator used as disease-modifying therapy for multiple sclerosis.

Full Definition

Fingolimod is an oral immunomodulatory drug that acts as a sphingosine-1-phosphate receptor modulator, effectively sequestering lymphocytes in lymph nodes and reducing their migration into the central nervous system. It was the first oral disease-modifying therapy approved for relapsing forms of multiple sclerosis. The drug requires cardiac monitoring due to potential bradycardia and requires ophthalmological surveillance for macular edema. Fingolimod represents a significant advancement in MS treatment, offering improved patient compliance compared to injectable therapies while maintaining efficacy in reducing relapse rates and disease progression.

Usage

Usage note: Brand name Gilenya should be capitalized; generic name fingolimod is lowercase.

In Context

  • "The patient was transitioned from interferon therapy to fingolimod due to injection-site reactions." — Clinical case note
  • "Fingolimod treatment resulted in a 54% reduction in annualized relapse rate compared to placebo." — Clinical trial report

Also known as

FTY720 Gilenya

Don't confuse with

dimethyl fumarate teriflunomide

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON